About HBM Partners
HBM Partners is a private equity firm founded in 2001. It is primarily based in Zug, Switzerland. In the last 12 months, it has participated in 1 funding round.
Overall HBM Partners portfolio has seen 2 unicorns, 37 IPOs and 53 acquisitions including key companies like Tata 1mg, C4 Therapeutics and SpringWorks Therapeutics. A lot of funds co-invest with HBM Partners, with names like HBM Healthcare Investments sharing a substantial percentage of its portfolio.
HBM Partners has a team of 26 people, including 10 partners.
Key Metrics
HBM Partners' Portfolio
They have invested in a total of 142 companies. Their most recent investment was in Electra Therapeutics (Series C round) on Oct 15, 2025. Here is the most recent investment by HBM Partners:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Oct 15, 2025 | Series C | 5397 | ||
Mar 30, 2022 | Series C | 9077 | ||
Feb 07, 2022 | Series A | 2164 | ||
Dec 09, 2021 | Series C | 3348 |
Here is the portfolio snapshot of HBM Partners:
Investments by Year
The maximum number of investments were made in 2019
Team profile of HBM Partners
HBM Partners has a team of 26 members including 10 Partners and 3 Principals located in Switzerland, Sweden and 1 more location. HBM Partners' team does not sit on the board of any company as of now.Here is a list of top team members in HBM Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Zurich | - | ||
Partner | Switzerland | - | - | |
Partner | Zurich | - | ||
Partner | Zurich | - | ||
Partner | Zurich | - | ||
Partner | Zurich | - | ||
Partner | Zurich | - | - | |
Partner | Geneva | - | - | |
Partner | Lucerne | - | ||
Partner | - | - | ||
Principal | Zurich |
Co-investors of HBM Partners
Over the past 25 years, 153 investors have co-invested in HBM Partners's portfolio companies.
- Top Co-investors of HBM Partners: 153 investors entered a company along with HBM Partners. These include investors like HBM Healthcare Investments (8 companies).
HBM Partners News
•
J&J scoops up another atopic dermatitis antibody in $1.25B Numab rights dealFierce Biotech•May 28, 2024•Johnson & Johnson, Numab, Iandisoft, Novo Holdings and 6 others
•
•
The Swiss biotech with an Italian heart Cutiss opens a new round with a collection target of 40 million eurosBeBeez•Oct 02, 2023•CUTISS, Giulianipharma, Royalty Pharma, HBM Partners and 3 others
•
Neuron23 Closes $100 Million Series Csvdaily.com•Mar 31, 2022•Neuron23, SoftBank Vision Fund, Westlake Village Biopartners, Kleiner Perkins and 6 others
•
Irish Neurovascular Firm Perfuze Raises $25M for Novel Stroke TreatmentMedical Product Outsourcing•Feb 09, 2022•Perfuze, Life Sciences Partners, Seroba Lifesciences, SV Health Investors and 7 others
•
Novo, HBM lead CHF 100m round for NumabUnquote•May 20, 2021•Novo Holdings, HBM Partners, Numab, Forbion and 5 others
•
Genalyte Announces Oversubscribed $50 Million Financing Round to Expand Testing Menu and Deploy PlatformPR Newswire•Jan 11, 2021•Genalyte, Verily, Provenio Capital, Redmile Group and 4 others
•
Neuron23 Closes $113.5M Series A and B FinancingFinSMEs•Dec 16, 2020•Neuron23, Westlake Village Biopartners, Kleiner Perkins, Redmile Group and 5 others
•
Clear Labs raises $18 million to expand its automated next-generation sequencing platform for COVID-19 diagnosticsTechStartups.com•May 14, 2020•Clear Labs, Redmile Group, Wing Venture Capital, Menlo Ventures and 8 others
•
iTeos Therapeutics Raises $125M in Series B2 FundingFinSMEs•Apr 01, 2020•iTeos Therapeutics, RA Capital Management, Boxer Capital, Janus Henderson Investors and 14 others
